CLINICAL TRIALS PROFILE FOR FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

505(b)(2) Clinical Trials for Fluconazole In Sodium Chloride 0.9%

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT02372357 ↗	A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area	Completed	Institutul Clinic Fundeni	Phase 4	2012-02-01	A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.
New Dosage	NCT02372357 ↗	A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area	Completed	Institutul Clinic Fundeni Bucharest	Phase 4	2012-02-01	A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.
New Dosage	NCT02372357 ↗	A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area	Completed	Universitaire Ziekenhuizen Leuven	Phase 4	2012-02-01	A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.
New Indication	NCT04495608 ↗	Fluconazole in Hypercalciuric Patients With Increased 1,25(OH)2D Levels	Recruiting	Hospices Civils de Lyon	Phase 2	2021-01-13	Hypercalciuria is one of the most frequent metabolic disorders associated with nephrolithiasis and/or nephrocalcinosis leading to Chronic Kidney Disease (CKD) and bone complications in adults. Hypercalciuria can be secondary to increased intestinal absorption and/or increased renal distal tubular reabsorption of calcium due to increased active vitamin D, i.e. 1,25(OH)2D, levels. The management of hypercalciuria is challenging. Classic management based on hyperhydration and dietary advice has low impact on calciuria and therefore on CKD progression. Other strategies such as hydrochlorothiazide can be proposed, however with an uncertain medical benefit in view of side effects (hypokalemia, asthenia, potential cutaneous long-term side effects). Azoles are known to inhibit the 1α-hydroxylase and therefore decrease 1,25(OH)2D levels. These antifungal drugs are commonly used in neonates, infants and adults; pharmacokinetic data are well described. Recently, to improve azoles tolerance, fluconazole has been successfully reported to reduce calciuria in patients with CYP24A1 mutation (1 adult) or NPTIIc mutations (1 child), while maintaining a stable renal function. Based on these observations, the investigators hypothesize that fluconazole is effective to decrease and normalize calciuria in patients with hypercalciuria and increased 1,25(OH)2D levels. The primary objective is to demonstrate that fluconazole normalizes or decreases calciuria after 4 months of treatment in patients with hypercalciuria and increased 1,25(OH)2D levels. The secondary objectives aim to describe: - the effects of fluconazole on the evolution over time of the calcium/phosphate metabolism, - the evolution of renal function, - the cohort at Baseline and after 4 months of treatment period, - the safety of fluconazole, - the onset of potential mycological resistances, - and the treatment compliance. This is a prospective, interventional, national, randomized in 2 parallel groups (1:1), controlled versus placebo, double blind trial. This study will involve patients between 10 and 50 years of age suffering from nephrolithiasis and/or nephrocalcinosis with hypercalciuria (> 0.1 mmol/kg/d) and increased 1,25 (OH)2D levels (≥ 150 pmol/l) and 25-OH-D levels (≥50 nmol/L). FLUCOLITH study is a unique opportunity to develop a new indication of a well-known and not expensive drug (e.g. fluconazole) in rare renal diseases, the ultimate objective being the secondary prevention of CKD worsening in these patients. If the results of this proof-of-concept randomized controlled trial are positive, the investigators will propose an extension phase to evaluate the long term efficacy and safety of fluconazole on renal and bone parameters.
OTC	NCT05059145 ↗	A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis	Not yet recruiting	Karolinska Institutet	Phase 2	2021-10-01	The overall aim of this study is to investigate if vaginally applied 1% chlorhexidine gluconate (CHG) could be an alternative treatment to oral fluconazole (FLZ), both during an acute episode and as prophylaxis, against recurrent infections of vulvovaginal candidiasis (RVVC). RVVC is very common in fertile women. Up to six months of treatment with FLZ is recommended for RVVC. Over the last ten years, the use of FLZ has increased markedly in many countries. No major problems have been noted with resistance development, but there is concern that this will occur in the future and alternative treatments are requested. In recent years, it has emerged that flukonazol interacts with several different types of drugs that are common in the patient group; several antidepressants, pain relief at dysmenorrhea (NSAID) and oral contraceptives to name a few. In Sweden an over-the-counter vaginal cream consisting of 1% chlorhexidine gluconate (Hibitane®) is available with the indication antiseptic use in vaginal examinations, especially during childbirth. The product has been used for a long time in various gynecological and obstetric surgical procedures. Hibitane® is approved during pregnancy and the cream is usually well tolerated. Our research group has previously done an in vitro study in which we analyzed the effect of FLZ and CHG's ability to kill fungal cells and to break down existing biofilm or prevent new biofilm formation. The biofilm formation is an important stage for the fungal cells to attach to surfaces such as skin and mucosa and is considered a first step in the development of an infection. In the biofilm, the fungus can hide from the immune system and also to some extent for various treatments aimed against the fungus. The results of the study showed that CHG was better than FLZ both at killing the fungal cells and preventing new biofilm from forming and dissolving already established "old" biofilm. This effect is absolutely crucial for successful treatment with antimycotics. These encouraging results form the basis of the planned study. If CHG is at least as effective as FLZ with little impact on vaginal lactobacillus, with high tolerability and without cytotoxic effect on epithelial cells, the results of the study might lead to major benefits to the patients with reduced risk of systemic side effects such as drug interactions, development of drug resistance and reduced drug costs.

All Clinical Trials for Fluconazole In Sodium Chloride 0.9%

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000627 ↗	Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome	Completed	Pfizer	N/A	1969-12-31	To evaluate the use of fluconazole as (1) induction therapy in histoplasmosis, (2) maintenance therapy to prevent relapse of histoplasmosis. Histoplasmosis is a serious opportunistic infection in patients with AIDS. Fluconazole is a triazole antifungal agent that has been used successfully in the treatment of experimental histoplasmosis in animals, but has not been completely evaluated in patients for this use. It has been approved by the Food and Drug Administration for certain other fungal infections. Nevertheless, physicians are prescribing it to their patients with histoplasmosis. This is a pilot study to examine the role of fluconazole for treating histoplasmosis in AIDS patients.
NCT00000627 ↗	Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To evaluate the use of fluconazole as (1) induction therapy in histoplasmosis, (2) maintenance therapy to prevent relapse of histoplasmosis. Histoplasmosis is a serious opportunistic infection in patients with AIDS. Fluconazole is a triazole antifungal agent that has been used successfully in the treatment of experimental histoplasmosis in animals, but has not been completely evaluated in patients for this use. It has been approved by the Food and Drug Administration for certain other fungal infections. Nevertheless, physicians are prescribing it to their patients with histoplasmosis. This is a pilot study to examine the role of fluconazole for treating histoplasmosis in AIDS patients.
NCT00000639 ↗	A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis	Completed	Washington University School of Medicine	N/A	1969-12-31	To evaluate the effectiveness and safety of amphotericin B plus flucytosine (5-fluorocytosine) compared to amphotericin B alone for a first episode of acute cryptococcal meningitis in AIDS patients, and to compare the effectiveness and safety of fluconazole versus itraconazole. At least 10 percent of patients with a low CD4 count and HIV infection will develop meningitis due to Cryptococcus neoformans. More effective treatments than the standard therapy need to be explored.
NCT00000639 ↗	A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To evaluate the effectiveness and safety of amphotericin B plus flucytosine (5-fluorocytosine) compared to amphotericin B alone for a first episode of acute cryptococcal meningitis in AIDS patients, and to compare the effectiveness and safety of fluconazole versus itraconazole. At least 10 percent of patients with a low CD4 count and HIV infection will develop meningitis due to Cryptococcus neoformans. More effective treatments than the standard therapy need to be explored.
NCT00000676 ↗	Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081)	Completed	Pfizer	Phase 3	1969-12-31	To study the effectiveness, safety, and tolerance of fluconazole versus clotrimazole troches (lozenges) as prophylaxis (preventive treatment) against fungal infections in patients enrolled in ACTG 081 (a study of prophylaxis against pneumocystosis, toxoplasmosis, and serious bacterial infection). Primarily, to compare the rates of invasive infections by C. neoformans, endemic mycoses, and Candida. To compare the mortality rates due to fungal infections between two antifungal prophylactic treatments. Secondarily, to assess the effect of prophylaxis on the incidence of severe fungal infections, defined as invasive infections and esophageal candidiasis and less severe mucocutaneous infection. Serious fungal infections are significant complicating and life-threatening occurrences in patients with advanced HIV infection. Oropharyngeal candidiasis is found in almost all such patients, and causes pain, difficulty in swallowing, and loss of appetite. Similarly, esophageal candidiasis causes illness in the population. Cryptococcosis, endemic mycoses, and coccidioidomycosis also cause significant illness and death in AIDS patients. Once established, fungal infections in AIDS patients generally require continuous suppressive therapy because attempts at curing these infections are usually unsuccessful. Fluconazole has a number of characteristics that would make it a logical candidate to examine as a prophylactic agent in patients with advanced HIV infection. Animal studies have shown it to be prophylactic in models of candidiasis, cryptococcosis, histoplasmosis, and coccidioidomycosis. Initial experience in patients with active cryptococcal meningitis appears favorable, and studies of oropharyngeal candidiasis show it to be effective.

Clinical Trial Conditions for Fluconazole In Sodium Chloride 0.9%

Condition Name

Condition Name for Fluconazole In Sodium Chloride 0.9%
Intervention	Trials
HIV Infections	42
Candidiasis	21
Mycoses	19
Meningitis, Cryptococcal	16

Condition MeSH

Condition MeSH for Fluconazole In Sodium Chloride 0.9%
Intervention	Trials
Candidiasis	77
HIV Infections	45
Mycoses	45
Infections	31

Clinical Trial Locations for Fluconazole In Sodium Chloride 0.9%

Trials by Country

Trials by Country for Fluconazole In Sodium Chloride 0.9%
Location	Trials
United States	771
China	36
Canada	28
Spain	20
Belgium	15

Trials by US State

Trials by US State for Fluconazole In Sodium Chloride 0.9%
Location	Trials
California	57
Texas	55
Florida	46
New York	46
Pennsylvania	40

Clinical Trial Progress for Fluconazole In Sodium Chloride 0.9%

Clinical Trial Phase

Clinical Trial Phase for Fluconazole In Sodium Chloride 0.9%
Clinical Trial Phase	Trials
PHASE4	6
PHASE3	4
PHASE2	4

Clinical Trial Status

Clinical Trial Status for Fluconazole In Sodium Chloride 0.9%
Clinical Trial Phase	Trials
Completed	189
Recruiting	28
Unknown status	21

Clinical Trial Sponsors for Fluconazole In Sodium Chloride 0.9%

Sponsor Name

Sponsor Name for Fluconazole In Sodium Chloride 0.9%
Sponsor	Trials
Pfizer	40
National Institute of Allergy and Infectious Diseases (NIAID)	25
Merck Sharp & Dohme Corp.	7

Sponsor Type

Sponsor Type for Fluconazole In Sodium Chloride 0.9%
Sponsor	Trials
Other	231
Industry	168
NIH	46

Last updated: May 20, 2026

Fluconazole in Sodium Chloride 0.9% (IV) Clinical Trials Update, Market Analysis, and Forecast

Executive summary: Fluconazole in sodium chloride 0.9% (0.9% NaCl) is an intravenous (IV) antifungal formulation marketed for invasive fungal infections and related systemic mycoses. Public clinical-trial activity is largely driven by (1) fluconazole’s long-standing active ingredient evidence base, (2) formulation/bioequivalence and product-specific comparability work for IV brands and generics, and (3) safety and dosing studies in defined patient populations. Market projections depend primarily on hospital and acute-care demand for IV antifungal therapy, antimicrobial stewardship dynamics, and pricing pressure from generic IV fluconazole entries. In most markets, exclusivity is already expired for the active ingredient; remaining IP exposure typically sits in formulation and manufacturing-process patents, plus country-by-country data protections tied to specific product approvals.

Because fluconazole IV is an established genericized product category in many geographies, “clinical trials update” for this exact admixture is usually incremental (comparability, PK, and local tolerance) rather than new Phase 3 efficacy programs against the same fungal indications.

How is “fluconazole in sodium chloride 0.9%” positioned in the fluconazole product portfolio?

For drug-approval and purchasing workflows, the relevant distinction is the dosage form and diluent system, not a distinct active pharmaceutical ingredient (API). Fluconazole in 0.9% NaCl is the IV presentation where fluconazole is supplied in an isotonic saline vehicle suitable for hospital administration.

Holders and marketers typically sell:

• IV solution strengths (common clinical use patterns: 2 mg/mL and 10 mg/mL ranges depending on product)
• Dose-ready bags/vials for infusion or direct administration per label
• Aseptic manufacturing with defined stability and compatibility claims

---

Which clinical trials support IV fluconazole in 0.9% saline, and what is the latest update?

Featured snippet answer: The clinical evidence base for IV fluconazole is dominated by historical efficacy and safety data for fluconazole across systemic fungal indications, with the most recent studies in many cases focused on formulation comparability (bioequivalence/PK) rather than new clinical endpoints.

What trial types exist specifically for IV fluconazole products?

Most “new” studies tied to IV fluconazole in NaCl 0.9% fall into these buckets:

• Bioequivalence and pharmacokinetic (PK) bridge studies between IV products (originator vs. generic; or generic vs. another generic manufacturer’s product line).
• Stability and reconstitution/infusion performance studies (often protocolized as technical clinical quality work rather than efficacy trials).
• Population PK and safety evaluations in renal impairment, pediatrics, and ICU cohorts.
• Therapeutic drug monitoring (TDM) feasibility in high-risk populations, when included.

What indications remain the dominant use cases?

Clinical use patterns for IV fluconazole typically center on:

• Invasive candidiasis (selected regimens depending on species and clinical setting)
• Esophageal candidiasis when IV administration is used for patients unable to take oral therapy
• Other systemic candidal infections and fungal syndromes covered by labeled indications in each jurisdiction

What does the current “clinical trials update” usually look like for this formulation?

For a commodity IV antifungal, current trial activity is typically:

• Sparse relative to newer antifungals
• Concentrated in comparability rather than new efficacy Phase 3 programs
• More visible in trials databases as manufacturer-specific PK/BE or observational safety registry work

---

What endpoints and comparators are used in PK/bioequivalence studies for fluconazole IV in saline?

Featured snippet answer: IV fluconazole PK/BE work commonly uses serum concentration-time metrics (AUC, Cmax, T_last or equivalent) to demonstrate exposure similarity between the test IV product and a reference.

Typical PK/BE metrics

• AUC (area under the curve) for total exposure
• Cmax for peak concentration
• tmax and terminal half-life parameters (product and assay dependent)
• Renal clearance correlations in controlled cohorts

Who are the study populations?

• Healthy volunteers for BE when feasible
• Renal impairment cohorts when the protocol targets dose adjustment evidence or exposure shift characterization
• ICU or hospitalized cohorts in observational programs, though less common for strict BE

What formulation variables matter most for IV fluconazole?

For this admixture, key differentiators across brands and generics tend to be:

• Concentration and container system (bag vs. vial; polymer compatibility)
• pH and ionic profile within stability specifications
• Overfill and extractable/leachables controls (manufacturing and device-driven)
• Aseptic process controls (terminal sterilization vs. sterile filtration, depending on product)

---

How strong is the patent estate for fluconazole in sodium chloride 0.9% IV, and what patents block generics?

Featured snippet answer: Active ingredient IP for fluconazole is long expired. Barriers to generic competition for this specific IV admixture usually come from formulation-, container-, and manufacturing-process patents, plus product-specific regulatory exclusivity (where any remains) tied to specific approved dossiers in certain jurisdictions.

What patent categories typically exist for commodity IV solutions?

Common residual IP categories include:

• Formulation patents (specific concentrations, stability-enhancing excipients, pH windows, or physicochemical properties)
• Container closure system patents (bags/vials and compatibility)
• Manufacturing method patents (aseptic processing parameters, sterilization/filtration method, hold-time and mixing steps)
• Stability and shelf-life claims with controlled parameters

What is the practical litigation risk profile?

In mature drug categories, litigation is typically:

• Less frequent than for new drugs
• More likely when a company challenges a branded/older generic holder’s specific dossier or when a market has limited suppliers

---

When does fluconazole in 0.9% NaCl lose exclusivity, and what are the generic launch windows?

Featured snippet answer: For fluconazole IV, active ingredient exclusivity has largely expired in most regulated markets. Remaining exclusivity, if any, is typically tied to a particular product’s regulatory data protection or to a specific formulation/device approval, not to the fluconazole molecule itself.

Key drivers of market entry timing

• Regulatory data protection windows in each country tied to a specific NDA/MAA
• Patent expirations on container closure and stability or manufacturing process
• Operational entry lead time (aseptic manufacturing capacity, supply approvals)

What determines “first generic” vs “next generic” dominance?

• Price erosion pace based on number of qualified suppliers
• Procurement contracts and panel access
• Hospital formulary decisions and switching friction
• Supply continuity and recall-free track records

---

What is the Orange Book status of fluconazole IV in sodium chloride 0.9%, and how many ANDAs exist?

Featured snippet answer: The U.S. Orange Book listings for IV fluconazole products are generally numerous, reflecting extensive generic competition. The detailed status (application numbers, patent numbers, listed use patents, and expiration dates) is product-specific and must be read at the exact NDC level.

Because this request requires exact Orange Book listing and patent numbers, the response would need the relevant NDC/NDA identifiers. Without those identifiers, a complete and accurate Orange Book mapping cannot be produced.

---

What Paragraph IV challenges and FDA ANDA litigation affect fluconazole IV in 0.9% NaCl?

Featured snippet answer: For fluconazole IV, Paragraph IV activity tends to be limited and localized because the active ingredient is off-patent and the product is highly genericized. The remaining cases, when present, relate to formulation, manufacturing, or device-related listed patents for specific products.

A complete litigation update requires direct linkage to the relevant Orange Book patents/NDCs and corresponding dockets. Without that product-to-patent mapping, an accurate statement on specific Paragraph IV cases cannot be provided.

---

How does fluconazole in 0.9% NaCl compare with other IV antifungals on uptake and substitution risk?

Featured snippet answer: Fluconazole’s clinical positioning is shaped by spectrum, species coverage, and cost. Compared with newer agents, substitution risk is lower from a mechanism standpoint when clinicians face fluconazole resistance or need broader coverage; substitution risk is higher when patients are stable, cultures are pending or Candida species are likely susceptible, and budget constraints favor older triazoles.

Substitution dynamics in hospitals

• Hospitals use fluconazole IV when coverage is appropriate and stewardship protocols permit narrow-spectrum selection.
• Broad-spectrum antifungals often capture use in:
  • suspected invasive fungal disease with uncertain etiology,
  • high-risk units with resistant pathogens,
  • empiric strategies where guideline-driven breadth is preferred.

Economic substitution

• Commodity pricing makes fluconazole a default option when dosing and species susceptibility align.
• Budget-driven switching pushes increased share to the lowest-cost qualified supplier once procurement contracts open.

---

Market analysis: where does demand come from for IV fluconazole in saline, and what is the competitive structure?

Executive summary: Demand is concentrated in acute care: oncology, ICU, and transplant pathways, plus hospital formularies for systemic candidiasis and candidal esophagitis when IV is required. The competitive structure is typically dominated by multiple generic suppliers with price leadership by contract manufacturers in each geography. Brand premium is minimal once generics are established.

Demand drivers

• Growing invasive candidiasis burden in high-risk populations
• ICU length of stay and prophylaxis/therapy cycles
• Increased antifungal stewardship scrutiny that can favor narrower agents when appropriate
• Supply reliability and procurement-driven switching among generic equivalents

Competitive landscape

• Multi-supplier generic IV fluconazole portfolios
• Competition by:
  • unit price and contract pricing,
  • availability and lead times,
  • perceived quality and packaging compatibility,
  • formulary preference by therapeutic interchange rules.

---

Market projection: what revenue and volume trends are likely through the forecast horizon?

Featured snippet answer: For IV fluconazole in 0.9% NaCl, forecasts typically show stable-to-moderate volume growth with continued price compression, yielding flat-to-low growth revenue depending on contract outcomes and supplier consolidation.

What typically happens to pricing

• New generic entries drive initial price drops
• Ongoing procurement cycles maintain downward pressure
• Price stabilization can occur if supply constrains or if fewer suppliers remain qualified

What typically happens to volume

• Volume increases track:
  • hospital admission trends in high-risk cohorts,
  • infection incidence changes,
  • guideline adoption patterns,
  • IV utilization shifts (oral switch readiness affects IV duration)

What makes the forecast sensitive?

• Resistance trends and guideline updates affecting fluconazole suitability
• Formulary changes and therapeutic interchange restrictions
• Manufacturing disruptions or quality events in supplier networks

---

Commercial forecast scenarios: base case, downside, and upside

Featured snippet answer: A base case expects continued generic share stability with price compression; upside assumes either supply-driven market stabilization or increased IV utilization; downside assumes resistance-guideline shifts away from fluconazole or supply outages reducing qualified availability.

Base case

• Moderate volume growth, revenue limited by contracting and price erosion
• Generic market share remains fragmented with procurement-driven winners

Downside

• Greater use of alternative triazoles or echinocandins for empiric or resistant cases
• Higher switching to broader spectrum therapy under stewardship protocols

Upside

• Sustained hospital usage for susceptible Candida scenarios
• Supply stabilization that supports steadier contract pricing and reduces extreme price bids

---

Regulatory pathway: how do ANDAs get approved for IV fluconazole solutions in NaCl 0.9%?

Featured snippet answer: In the U.S., most generic IV fluconazole solutions follow Abbreviated New Drug Application (ANDA) pathways predicated on bioequivalence and product-specific chemistry, manufacturing, and controls (CMC). Product-specific stability, container closure, and infusion performance are central to approvals.

What CMC elements are typically scrutinized for IV admixtures?

• Sterility assurance and aseptic controls
• Container compatibility with saline and drug concentration
• Stability under labeled storage conditions
• Extractables/leachables controls for container system

---

What formulation and manufacturing IP barriers block biosimilars or “follow-on” competition?

Featured snippet answer: Biosimilars are not applicable to fluconazole because it is a small molecule. “Follow-on” competition is generic substitution. Barriers come from formulation and manufacturing process patents (if any remain for specific SKUs) and regulatory data exclusivity at the product level.

---

Key Takeaways

• Clinical evidence for IV fluconazole remains anchored to the historical fluconazole efficacy and safety package; current product-specific work is more likely to be PK/BE and formulation comparability than new Phase 3 outcomes.
• Market structure is mature: multiple generic suppliers, contract-driven pricing, and limited room for premium unless supply or quality issues shift procurement outcomes.
• Exclusivity and patent risk for the fluconazole molecule has largely ended; remaining risks are SKU-level and geography-level tied to formulation/manufacturing patents and any product-specific regulatory data protections.
• Forecast is typically volume-stable to modestly growing with ongoing price compression, creating a flat-to-low revenue growth profile unless supply constraints or formulary changes support pricing.

---

FAQs

1. What are the most common IV dosing patterns for fluconazole used in hospitals?
2. How does renal impairment change the recommended IV fluconazole dose and exposure?
3. Which Candida species show reduced susceptibility where fluconazole IV is less preferred?
4. Do container types (bag vs vial) affect stability and administration compatibility for IV fluconazole in NaCl 0.9%?
5. What procurement levers most influence which generic suppliers win hospital contracts for IV fluconazole?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Guidance for Industry: Bioequivalence Studies Submitted in NDAs or INDAs: General Considerations. U.S. Food and Drug Administration.
3. ClinicalTrials.gov. Fluconazole intravenous studies and formulation comparability records. U.S. National Library of Medicine.